Статья
ВЫСОКОИНТЕНСИВНАЯ ГИПОЛИПИДЕМИЧЕСКАЯ ТЕРАПИЯ И НИЗКИЙ УРОВЕНЬ ХОЛЕСТЕРИНА ЛИПОПРОТЕИДОВ НИЗКОЙ ПЛОТНОСТИ: ОПРАВДАН ЛИ ТАКОЙ ПОДХОД В КЛИНИЧЕСКОЙ ПРАКТИКЕ? ВЗГЛЯД НА ПРОБЛЕМУ
Представленный обзор посвящен проблеме высокоинтенсивной терапии. Представлены доказательства эффективности назначения статинов в режиме высокой интенсивности пациентам очень высокого сердечно-сосудистого риска. Обозначены показания к такой терапии в первичной и вторичной профилактике. Рассматриваются вопросы переносимости и безопасности высокоинтенсивной терапии.
1. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal 2017; 38: 2459-72. DOI: 10.1093/eurheartj/ehx144.
2. Holmes MV, Asselbergs FW, Palmer TM, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J 2015; 36: 539-50. DOI: 10.1093/eurheartj/eht571.
3. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Eur Heart J 2016; 37: 2999-3058. DOI: 10.1093/eurheartj/ehw272.
4. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1–Full Report J Clinical Lipidology 2015; 9: 129-69.DOI:10.1016/j.jacl.2015.02.003.
5. Ежов М. В., Сергиенко И. В., Аронов Д. М. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза Российские рекомендации VI пересмотр. Атеросклероз и дислипидемии. 2017; 3 (28): 5-22.
6. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists’ (CTT) Collaboration, Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81. DOI: 10.1016/S0140-6736(10)61350-5.
7. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388: 2532-61. DOI: 10.1016/S01406736(16)31357-5.
8. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 2016; 316: 1289-97. DOI: 10.1001/jama.2016.13985.
9. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-8. PMID: 11277825.
10. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 N Engl J Med 2004; 350:.1495-504. DOI: 10.1056/NEJMoa040583.
11. Wiviott SD, Cannon CP, Morrow DA, et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005; 46: 1411-6. DOI: 10.1016/j.jacc.2005.04.064.
12. Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372: 2387-97. DOI: 10.1056/NEJMoa1410489.
13. Sabatine MS, Giugliano RP, Keech AC, et al. FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376: 1713-22. DOI: 10.1056/NEJMoa1615664.
14. Koskinas КC, Siontis GCM, Piccolo R, et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials Eur Heart J 2018; 39; 1172-80. DOI: 10.1093/eurheartj/ehx566.
15. Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol 2007; 99: 410-4. DOI: 10.1016/j.amjcard.2006.08.051.
16. Hwang D, Kim HK, Lee JM, et al. The KAMIR Investigators. Effects of Statin Intensity on Clinical Outcome in Acute Myocardial Infarction Patients. Circ J 2018; 82: 1112-20. DOI: 10.1253/circj.CJ-17-1221.
17. Boekholdt SM, Hovingh GK, Mora S, et al. Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events A Meta-Analysis of Statin Trials JACC, 2014; 5: 485-94. DOI: 10.1016/j.jacc.2014.02.615.
18. Giugliano RP, Pedersen TR, Park JG, et al. FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017; 390: 1961-71. DOI: 10.1016/S0140-6736(17)32290-0.
19. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association Of Clinical Endocrinologists And American College Of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease — executive summary. Endocr Pract. 2017; 23 (4): 479-97. DOI: 10.4158/EP171764.GL.
20. Bertoluci MC, Moreira RO, Faludi A, et al. Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM). Diabetol Metab Syndr. 2017; 9: 53. DOI: 10.1186/s13098-017-0251-z.
21. Ridker PM, Danielson E, Fonseca EAH, et al. Rosuvastatin to prevent vascular events in men women with elevated C-Reactive Protein. N Engl J Med. 2008; 359: 2195-207. DOI: 10.1056/NEJMoa0807646.
22. Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol
23. Fernández-Friera L, Fuster V, López-Melgar B, et al. Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors. J Am Coll Cardiol 2017; 70: 2979-91. DOI: 10.1016/j.jacc.2017.10.024.
24. Tsujita K, Sugiyama S, Sumida H, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISEIVUS trial. J Am Coll Cardiol 2015; 66: 495-507. DOI: 10.1016/j.jacc.2015.05.065.
25. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011; 365: 2078-87. DOI: 10.1056/NEJMoa1110874.
26. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial. JAMA 2004; 291: 1071-80. DOI: 10.1001/jama.291.9.1071.
27. Crouse III JR, Raichlen JS, Evans GW, et al. Effects of Rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical аtherosclerosis. The METEOR trial. JAMA 2007; 297: 1344-53. DOI: 10.1001/jama.297.12.1344.
28. Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients. The GLAGOV randomized clinical trial. JAMA 2016; 316: 2373-84. DOI: 10.1001/jama.2016.16951.
29. Kataoka Y, Hammadah M, Puri R, et al. Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels. Atherosclerosis, 2015; 242: 490-5. DOI: 10.1016/j.atherosclerosis.2015.08.005.
30. Falk E, Nakano M, Bentzon JF, et al. Update on acute coronary syndromes: the pathologists’ view. Eur. Heart J. 2013; 34: 719-28. DOI: 10.1093/eurheartj/ehs411.
31. Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions, Arterioscler. Thromb. Vasc. Biol. 2000; 20: 1262-75.
32. Puri R, Nissen SE, Libby P, et al. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy, Circulation, 2013; 128: 2395-403. DOI: 10.1161/CIRCULATIONAHA.113.004243.
33. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol 2012; 60: 2631-9. DOI: 10.1016/j.jacc.2012.09.017.
34. Vallejo-Vaz AJ, Robertson M, Catapano AL, et al. LDL-Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men with Primary Elevations of LDL-Cholesterol Levels of 190 mg/dL or Above: Analyses from the WOSCOPS 5-year Randomised Trial and 20-year Observational Follow-Up. Circulation, 2017; 136: 1876-91. DOI: 10.1161/CIRCULATIONAHA.117.027966.
35. Ference B. A naturally randomized trial comparing the effect of long-term exposure to LDL-C, lower SBP, or both on the risk of cardiovascular disease. European Society of Cardiology Congress 2016; August 29, 2016; Rome, Italy. Abstract 3163.
36. Descamps OS, Bruniaux M, Guilmot PF, et al. Lipoprotein concentrations in newborns are associated with allelic variations in their mothers. Atherosclerosis 2004; 172: 287-98. DOI: 10.1016/j.atherosclerosis.2003.11.002.
37. Chapman MJ. Animal lipoproteins: chemistry, structure, and comparative aspects. J Lipid Res 1980; 21: 789-853.
38. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science, 1986, 232, 34-47.
39. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781-90. DOI: 10.1016/S0140-6736(07)60716-8.